Company advances 3rd internally found program into clinical studies CAMBRIDGE, Mass.–(HSMN NewsFeed)–Acceleron Pharmaceutical, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blo…
Biopharmaceuticals, Oncology
Acceleron Pharma, ACE-041, angiogenesis, TGF-β, TGF-beta

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer”
Leave a Comment